Please ensure Javascript is enabled for purposes of website accessibility

Wall Street Selloff Sparked by Trump Tariffs, Amazon Results, Weak Payrolls

2 hours ago

US Construction Spending Extends Decline in June

2 hours ago

Global Shares in Red After US Jobs Data, Trump’s Tariff Salvo

2 hours ago

Construction of $200M Trump Ballroom at the White House to Begin in September

22 hours ago

US Senate Committee Backs $1 Billion for Ukraine in Pentagon Spending Bill

24 hours ago

Trump Says Mexico Trade Deal Extended for 90 Days

1 day ago

Fresno Unified Trustee Susan Wittrup Responds to $162,000 Payout

2 days ago
Can Oxford University Deliver COVID Vaccine for High Risk Groups by October?
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
July 21, 2020

Share

No early safety concerns.

Strong immune responses in both parts of the immune system.

Portrait of Dr. Adrian Hill

“We are seeing good immune response in almost everybody. What this vaccine does particularly well is, trigger both arms of the immune system.” — Dr. Adrian Hill, director, Jenner Institute at Oxford University

Those are the results from Oxford University’s Jenner Institute the world has been waiting for regarding a potential COVID-19 vaccine.

The most optimistic timeline is that the vaccine could be available on an emergency basis for high-risk groups as early as October.

British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are designed to evaluate the safety and gauge the immune response but don’t reveal if the vaccine truly protects.

US Trial of Vaccine Expected Soon

In research published Monday in the journal Lancet, scientists said that they found that the experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 lasting at least two months after injection.

A single dose of the vaccine dubbed AZD1222 resulted in a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. In all participants, a T-cell response was induced, peaking by day 14, and maintained for two months.

The experimental COVID-19 vaccine caused minor side effects like fever, chills, and muscle pain more often than in those who received a control meningitis vaccine.

“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is, trigger both arms of the immune system,” he said.

Hill said that larger trials evaluating the vaccine’s effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are ongoing. Another trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.

Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial and co-author of the trial, said, “We saw the strongest immune response in participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination.”

Image of a British doctor taking blood samples from a patient for COVID-19 research
A doctor takes blood samples for use in a coronavirus vaccine trial in Oxford, England, Thursday, June 25, 2020. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. (John Cairns, University of Oxford via AP)

October or December Timeframe

A report in the Economist says Oxford’s vaccine is in three late-stage trials. Only one other vaccine, developed by Sinopharm, a Chinese firm, has started a late-stage trial, and it does not have the global support and financing that Oxford’s does.

It might be clear by the end of August if the vaccine is effective. A single successful trial showing efficacy would allow a regulator to approve the vaccine for emergency use — something that would probably pave the way for use in high-risk groups. That could happen in October. The firm thinks that full approval, which would require results from multiple trials, could come early in 2021.

How quickly scientists determine the vaccine’s effectiveness will depend largely on how much more transmission there is, but Hill estimated that if there were enough data to prove the vaccine’s efficacy, immunization of some high-risk groups in Britain could begin in December.

Vaccine Distribution

Oxford is working with the U.K.-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture, and potential distribution of the vaccine, with plans for clinical development and production of the Oxford vaccine progressing globally.

Emergent BioSolutions Inc. will support the manufacturing of AstraZeneca’s vaccine candidate for COVID-19, AZD1222. Under the agreement, valued at approximately $87 million, Emergent will provide development services, technology transfer, analytical testing, drug substance process and performance qualification and will reserve certain large-scale manufacturing capacity through 2020.

Mike Neri, Emergent’s Senior Director of Corporate Communications tells GV Wire℠ by email, “The work is being done in Baltimore, Maryland.”

AstraZeneca’s AZD1222 is one of several candidates supported by Operation Warp Speed (OWS), the U.S. government’s program to accelerate the development, manufacturing, and distribution of COVID-19 medical countermeasures.

Numerous countries including Germany, France, the Netherlands, Italy, U.S,. and the U.K. have all signed deals to receive hundreds of millions of doses of the Oxford vaccine.

Image of vaccine blood samples at Oxford University
Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. In research published Monday, July 20, 2020, in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. (John Cairns, University of Oxford via AP)

‘Challenge’ Trial

Hill said researchers were also considering conducting a “challenge” trial by the end of 2020, an ethically controversial test where participants would be deliberately infected with COVID-19 after being immunized to see if the vaccine is effective.

“This has been done before in 19 different infectious diseases to develop vaccines and drugs and is likely to happen for COVID-19 as well,” he said.

Progress of Other Vaccines

Associated Press reported that Chinese researchers also published a study on their experimental COVID-19 vaccine in the Lancet on Monday. That vaccine uses a technique similar to Oxford’s. They reported that in a study of about 500 people, an immune response was detected in those who were immunized. But the Chinese scientists were unable to detect if people were protected from the disease because they weren’t exposed to COVID-19 afterwards.

Last week, American researchers announced that the first COVID-19 vaccine tested there boosted people’s immune systems just as scientists had hoped and the shots will now enter the final phase of testing. That vaccine, developed by the National Institutes of Health and Moderna, produced the molecules key to blocking infection in volunteers who got it, at levels comparable to people who survived a COVID-19 infection.

(Associated Press contributed to this report.)

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Fresno Councilmember Vang Accused of Conflict of Interest in Budget Vote

DON'T MISS

Ghislaine Maxwell Moved From Florida Prison to Lower-Security Facility

DON'T MISS

Trump Escalates Trade War With Canada Following Palestine Stance

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Scott Oscar Whitehead

DON'T MISS

‘Freedom Week’: California Gun Owners Rush to Buy Ammo After Court Ruling

DON'T MISS

Wall Street Selloff Sparked by Trump Tariffs, Amazon Results, Weak Payrolls

DON'T MISS

US Construction Spending Extends Decline in June

DON'T MISS

Global Shares in Red After US Jobs Data, Trump’s Tariff Salvo

DON'T MISS

US Envoy Witkoff Visits Aid Operation in Gaza Rejected by UN as Unsafe

DON'T MISS

Visalia Road Project to Temporarily Shut Down Part of Caldwell Avenue

UP NEXT

Trump Escalates Trade War With Canada Following Palestine Stance

UP NEXT

‘Freedom Week’: California Gun Owners Rush to Buy Ammo After Court Ruling

UP NEXT

US Construction Spending Extends Decline in June

UP NEXT

Global Shares in Red After US Jobs Data, Trump’s Tariff Salvo

UP NEXT

US Envoy Witkoff Visits Aid Operation in Gaza Rejected by UN as Unsafe

UP NEXT

Trump Sets 10% to 41% ‘Reciprocal’ Tariffs on Dozens of Countries’ Exports

UP NEXT

Countries With No Trade Deal Will Hear From US by Midnight, White House Says

UP NEXT

Trump’s Envoy Meets Netanyahu for Gaza Aid, Ceasefire Push

UP NEXT

Construction of $200M Trump Ballroom at the White House to Begin in September

UP NEXT

Yosemite’s Largest Campground Reopens Friday After $26.2 Million Renovation

Valley Crime Stoppers’ Most Wanted Person of the Day: Scott Oscar Whitehead

1 hour ago

‘Freedom Week’: California Gun Owners Rush to Buy Ammo After Court Ruling

2 hours ago

Wall Street Selloff Sparked by Trump Tariffs, Amazon Results, Weak Payrolls

2 hours ago

US Construction Spending Extends Decline in June

2 hours ago

Global Shares in Red After US Jobs Data, Trump’s Tariff Salvo

2 hours ago

US Envoy Witkoff Visits Aid Operation in Gaza Rejected by UN as Unsafe

2 hours ago

Visalia Road Project to Temporarily Shut Down Part of Caldwell Avenue

2 hours ago

Trump Sets 10% to 41% ‘Reciprocal’ Tariffs on Dozens of Countries’ Exports

17 hours ago

Fresno Fire Displaces Family of Three, Pets Rescued

19 hours ago

Measure C Advisory Group Still Squabbling but Agrees on Mission Statement

19 hours ago

Fresno Councilmember Vang Accused of Conflict of Interest in Budget Vote

Fresno City Councilmember Brandon Vang is on the radar of the state agency in charge of campaign finance enforcement. The Fair Political ...

8 minutes ago

8 minutes ago

Fresno Councilmember Vang Accused of Conflict of Interest in Budget Vote

Jeffrey Epstein associate Ghislaine Maxwell stands at the podium to address Judge Alison Nathan during her sentencing in a courtroom sketch in New York City, U.S. June 28, 2022. (Reuters File)
13 minutes ago

Ghislaine Maxwell Moved From Florida Prison to Lower-Security Facility

President Donald Trump and Canadian Prime Minister Mark Carney attend a meeting with G7 leaders and guests, at the G7 summit in Kananaskis, Alberta, Canada, June 16, 2025. (Reuters File)
25 minutes ago

Trump Escalates Trade War With Canada Following Palestine Stance

Scott Oscar Whitehead is Valley Crime Stoppers' Most Wanted Person of the Day for August 1, 2025. (Valley Crimes Stoppers)
1 hour ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Scott Oscar Whitehead

.25 Caliber Ammunition on the Counter at Big 5
2 hours ago

‘Freedom Week’: California Gun Owners Rush to Buy Ammo After Court Ruling

A Wall Street plate is seen on a street vendor stall outside the New York Stock Exchange (NYSE) in New York City, U.S., July 11, 2025. (Reuters/Jeenah Moon)
2 hours ago

Wall Street Selloff Sparked by Trump Tariffs, Amazon Results, Weak Payrolls

A construction worker is shown at work on a multi-unit residential housing project in Encinitas, California, U.S., July 28, 2025. (Reuters/Mike Blake)
2 hours ago

US Construction Spending Extends Decline in June

A trader works on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., July 30, 2025. (Reuters/Jeenah Moon)
2 hours ago

Global Shares in Red After US Jobs Data, Trump’s Tariff Salvo

Help continue the work that gets you the news that matters most.

Search

Send this to a friend